Lafti® B94 is a probiotic strain produced by canadian multinational company Lallemand Health Solutions.

This strain belongs to species Bifidobacterium animalis ssp. lactis, known for its capability to colonize the intestine; in-vitro studies showed that Lafti® B94 resists to harsh conditions typical of gastrointestinal system and to bile.

Lafti® B94 has been studied in co-formulation with different prebiotic fibers, showing a good synergy with FOS and Inulin, beside being capable of hydrolyzing resistant maltodextrin.

Several clinical studies, also leading to various health claims obtained in Canada, showed that Lafti® B94 is particularly beneficial in contrasting IBS-like symptoms, such as gut discomfort, bloating and constipation, especially in children.

This strain supports, especially and particularly in children, gastrointestinal health, significantly reducing occasional diarrhea symptoms (clinical study in a total of 156 children) and incidence of necrotizing colitis (in a a total of 400 pre-term ospitalized newborns)

Strain is available in bulk at a concentration of 100 billion CFU/g, with a shelf-life of 2 years at 2-8°C.